Search

Your search keyword '"Kimby, Eva"' showing total 24 results
Start Over Author "Kimby, Eva" Journal british journal of haematology
24 results on '"Kimby, Eva"'

2. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

Author

Owen, Roger G., Kyle, Robert A., Stone, Marvin J., Rawstron, Andy C., Leblond, Veronique, Merlini, Giampaolo, Garcia-Sanz, Ramon, Ocio, Enrique M., Morra, Enrica, Morel, Pierre, Anderson, Kenneth C., Patterson, Christopher J., Munshi, Nikhil C., Tedeschi, Alessandra, Joshua, Douglas E., Kastritis, Efstathios, Terpos, Evangelos, Ghobrial, Irene M., Leleu, Xavier, Gertz, Morie A., Ansell, Stephen M., Morice, William G., Kimby, Eva, and Treon, Steven P.

Published
2013
Full Text
View/download PDF

3. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non‐Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.

Author

Brandefors, Lena, Sander, Birgitta, Lundqvist, Kristina, and Kimby, Eva

Subjects
WALDENSTROM'S macroglobulinemia, TREATMENT effectiveness, PROGNOSIS, LYMPHOMAS, SURVIVAL rate
Abstract

Summary: Lymphoplasmacytic lymphoma (LPL) not fulfilling the WHO diagnostic criteria (2017) for Waldenstrom's macroglobulinemia (WM) (named non‐WM LPL) is a rare disease and only a few systematic studies have been published. Here, we present a population‐based study of non‐WM LPL focusing on diagnostic difficulties, patient characteristics, and outcome. From 1511 patients included in the Swedish Lymphoma Registry 1 Jan 2000 – 31 Dec 2014 with a diagnosis of WM/LPL, we could confirm the diagnosis of non‐WM LP in only 33 patients. The median age at diagnosis was 69 years. A paraprotein was found in most (IgG in 54%, IgA in 15%) and 12% of the cases were non‐secretory. Compared with the WM patients, the non‐WM LPL patients were younger, had more adverse prognostic factors such as elevated LDH, anaemia, and lymphocytosis at diagnosis. In addition, the non‐WM LPL patients more often were symptomatic and received treatment at diagnosis. The overall survival (OS) did not significantly differ between the non‐WM LPL and WM groups (P = 0.247), with a median survival time of 71 and 96 months, respectively. To conclude, we found differences in clinical features between WM and non‐WM LPL, but no difference in survival. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

4. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

Author

Geisler, Christian H., Kolstad, Arne, Laurell, Anna, Jerkeman, Mats, Räty, Riikka, Andersen, Niels S., Pedersen, Lone B., Eriksson, Mikael, Nordström, Marie, Kimby, Eva, Bentzen, Hans, Kuittinen, Outi, Lauritzsen, Grete F., Nilsson-Ehle, Herman, Ralfkiær, Elisabeth, Ehinger, Mats, Sundström, Christer, Delabie, Jan, Karjalainen-Lindsberg, Marja-Liisa, Brown, Peter, and Elonen, Erkki

Published
2012
Full Text
View/download PDF

7. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)

Author

Moccia, Alden Alberto, primary, Schär, Sämi, additional, Hayoz, Stefanie, additional, Pirosa, Maria Cristina, additional, Taverna, Christian, additional, Novak, Urban, additional, Kimby, Eva, additional, Ghielmini, Michele, additional, and Zucca, Emanuele, additional

Published
2020
Full Text
View/download PDF

10. Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy

Author

Menter, Thomas, primary, Tzankov, Alexandar, additional, Zucca, Emanuele, additional, Kimby, Eva, additional, Hultdin, Magnus, additional, Sundström, Christer, additional, Beiske, Klaus, additional, Cogliatti, Sergio, additional, Banz, Yara, additional, Cathomas, Gieri, additional, Karjalainen‐Lindsberg, Marja‐Liisa, additional, Grobholz, Rainer, additional, Mazzucchelli, Luca, additional, Sander, Birgitta, additional, Hawle, Hanne, additional, Hayoz, Stefanie, additional, and Dirnhofer, Stefan, additional

Published
2020
Full Text
View/download PDF

12. High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia

Author

Hallböök, Helene, Simonsson, Bengt, Ahlgren, Thomas, Björkholm, Magnus, Carneskog, Jan, Grimfors, Gunnar, Hast, Robert, Karlsson, Karin, Kimby, Eva, Lerner, Richard, Linder, Olle, Linderholm, Mats, Löfvenberg, Eva, Malm, Claes, Nilsson, Per-Gunnar, Paul, Christer, Stenke, Leif, Stockelberg, Dick, Tidefelt, Ulf, Turesson, Ingemar, Uden-Blome, Ann-Marie, Vilen, Lars, Wahlin, Anders, Winquist, Ingemar, and Smedmyr, Bengt

Published
2002
Full Text
View/download PDF

13. Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients

Author

Karlsson, Karin, Strömberg, Mats, Liliemark, Jan, Delannoy, André, Johnson, S. A. N, Porwit, Anja, Kimby, Eva, Lärfars, Gerd, Cristiansen, Ilse, Nilsson, Göran, Celsing, Fredrik, Sundström, Gunnel, Luthman, Mikaela, Tidefelt, Ulf, Wallvik, Jonas, and Juliusson, Gunnar

Published
2002

15. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).

Author

Moccia, Alden Alberto, Schär, Sämi, Hayoz, Stefanie, Pirosa, Maria Cristina, Taverna, Christian, Novak, Urban, Kimby, Eva, Ghielmini, Michele, and Zucca, Emanuele

Subjects
PROGNOSIS, CANCER research, LYMPHOMAS, RITUXIMAB
Abstract

Summary: The relapse of follicular lymphoma (FL) within 24 months (POD24) of chemoimmunotherapy has been associated with poor survival. We analyzed a pooled dataset of three randomized trials including FL patients with advanced disease, conducted by the Swiss Group for Clinical Cancer Research (SAKK). Overall, POD24 was observed in 27% of 318 patients, but rate variance among studies suggested that the rituximab schedule might affect POD24 rate. POD24 was associated with lower 10‐year overall survival rates than in the reference group (69% vs. 77%; hazard ratio, 3·12; 95% confidence interval, 1·73–5·65). POD24 retains its prognostic validity in patients treated without chemotherapy and may represent a useful end‐point for future studies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

16. M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy.

Author

Lockmer, Sandra, Ren, Weicheng, Brodtkorb, Marianne, Østenstad, Bjørn, Wahlin, Björn E., Pan‐Hammarström, Qiang, and Kimby, Eva

Subjects
RITUXIMAB, LYMPHOMAS, CLINICAL trials
Abstract

Summary: The clinical course of follicular lymphoma (FL) is highly variable. Recently the m7‐FL international prognostic index (FLIPI) integrating performance status, FLIPI score and the mutational status of seven genes, was shown to stratify patients into "low‐risk" and "high‐risk" with respect to 5‐year failure‐free survival after first‐line immunochemotherapy. Our aim was to evaluate the model after rituximab without chemotherapy. The Nordic Lymphoma Group performed two randomized clinical trials on indolent lymphoma patients receiving single rituximab and rituximab with interferon‐α2a. In total, 95 FL patients had sufficient fresh‐frozen diagnostic material for sequencing. A targeted panel for the genes EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP and CARD11 was utilized for m7‐FLIPI score calculation. With a median follow‐up of 10·6 years, 76% of patients were alive. No difference in time to treatment failure (TTF), defined as the interval between start of trial therapy and initiation of new therapy or death, nor overall survival (OS) was found between the m7‐FLIPI risk groups (log‐rank P = 0·94 and 0·99, respectively). EZH2 mutations were associated with longer TTF (log‐rank P = 0·04) and in EP300 mutations were associated with shorter TTF (log‐rank P = 0·01). We conclude that the prognostic value of the m7‐FLIPI clinicogenetic model seems dependent on therapeutic regimen. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

18. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes

Author

Palma, Marzia, primary, Krstic, Aleksandra, additional, Peña Perez, Lucia, additional, Berglöf, Anna, additional, Meinke, Stephan, additional, Wang, Qing, additional, Blomberg, K. Emelie M., additional, Kamali-Moghaddam, Masood, additional, Shen, Qiujin, additional, Jaremko, Georg, additional, Lundin, Jeanette, additional, De Paepe, Ayla, additional, Höglund, Petter, additional, Kimby, Eva, additional, Österborg, Anders, additional, Månsson, Robert, additional, and Smith, C. I. Edvard, additional

Published
2018
Full Text
View/download PDF

19. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

Author

Eskelund, Christian W., primary, Kolstad, Arne, additional, Jerkeman, Mats, additional, Räty, Riikka, additional, Laurell, Anna, additional, Eloranta, Sandra, additional, Smedby, Karin E., additional, Husby, Simon, additional, Pedersen, Lone B., additional, Andersen, Niels S., additional, Eriksson, Mikael, additional, Kimby, Eva, additional, Bentzen, Hans, additional, Kuittinen, Outi, additional, Lauritzsen, Grete F., additional, Nilsson-Ehle, Herman, additional, Ralfkiaer, Elisabeth, additional, Ehinger, Mats, additional, Sundström, Christer, additional, Delabie, Jan, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Workman, Christopher T., additional, Garde, Christian, additional, Elonen, Erkki, additional, Brown, Peter, additional, Grønbaek, Kirsten, additional, and Geisler, Christian H., additional

Published
2016
Full Text
View/download PDF

20. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

Author

Owen, Roger G., primary, Kyle, Robert A., additional, Stone, Marvin J., additional, Rawstron, Andy C., additional, Leblond, Veronique, additional, Merlini, Giampaolo, additional, Garcia-Sanz, Ramon, additional, Ocio, Enrique M., additional, Morra, Enrica, additional, Morel, Pierre, additional, Anderson, Kenneth C., additional, Patterson, Christopher J., additional, Munshi, Nikhil C., additional, Tedeschi, Alessandra, additional, Joshua, Douglas E., additional, Kastritis, Efstathios, additional, Terpos, Evangelos, additional, Ghobrial, Irene M., additional, Leleu, Xavier, additional, Gertz, Morie A., additional, Ansell, Stephen M., additional, Morice, William G., additional, Kimby, Eva, additional, and Treon, Steven P., additional

Published
2012
Full Text
View/download PDF

24. Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

Author

Geisler, Christian H., Kolstad, Arne, Laurell, Anna, Jerkeman, Mats, Räty, Riikka, Andersen, Niels S., Pedersen, Lone B., Eriksson, Mikael, Nordström, Marie, Kimby, Eva, Bentzen, Hans, Kuittinen, Outi, Lauritzsen, Grete F., Nilsson-Ehle, Herman, Ralfkiær, Elisabeth, Ehinger, Mats, Sundström, Christer, Delabie, Jan, Karjalainen-Lindsberg, Marja-Liisa, and Brown, Peter

Subjects
PUBLISHED errata, LYMPHOMAS
Abstract

A correction to the article "Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur" published in previous issue is presented.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results